InVivoMAb Anti-Human CD319 Antibody (TBS10350)

$489.00$2,399.00

Target: SLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1.

SKU: TBS10350 Categories: ,
SKUStock SIZE (mg) PriceQuantity
TBS10350-0.5MG Yes 0.5 MG $489.00
spinner
TBS10350-1MG Yes 1 MG $719.00
spinner
TBS10350-5MG Yes 5 MG $2,399.00
spinner

Description

InVivoMAb Anti-Human CD319 (SLAMF7) Antibody is a monoclonal antibody that specifically binds to human CD319, a cell surface receptor expressed on natural killer (NK) cells, plasma cells, and subsets of T cells. CD319 plays a key role in immune cell activation, adhesion, and cytotoxicity. This antibody is widely used in research to investigate immune cell signaling, antibody-dependent cellular cytotoxicity (ADCC), and potential therapeutic interventions in autoimmune diseases and cancer.

Synonyms

Anti-SLAMF7 antibody, Anti-CS1 antibody, Anti-CRACC antibody, Anti-CD2L antibody.

Product Details

Applications: ELISA, Neutralization, WB
Species reactivity: Human
Host: Human
Isotype: IgG1, kappa
Target: SLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1.
Uniprot: Q9NQ25
Concentration: 3 mg/ml
Purity: >95%
Formulation: Liquid
Storage buffer: 0.01M PBS, pH 7.4.
Purification: Protein A/G purified from cell culture supernatant.
Clonality: Monoclonal
Storage: Store -20°C up to 12 months, and -80°C for long term. Avoid repeated freeze-thaw cycles.

Data Image

 

 Fig. 1. SDS-PAGE for InVivoMAb Anti-Human CD319/SLAMF7 Antibody.

MW: Molecular Weight (kDa) Marker.

R: Reducing conditions.

NR: Non-Reducing conditions.

 

Research use only.

Additional information

SIZE (mg)

1 MG, 5 MG, 0.5 MG

Reviews

There are no reviews yet.


Be the first to review “InVivoMAb Anti-Human CD319 Antibody (TBS10350)”